MaaT Pharma has received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) for MaaT013 (Xervyteg) following re-examination for its conditional marketing authorisation application. The committee’s concerns relate primarily to the attribution of clinical benefit and safety in the absence of a randomised control trial. "We are deeply disappointed by […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!